Insulin Therapy in the Primary Care Setting

References: Introduction

1. Hogan P, Dall T, Nikolov P of the Lewin Group. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932.


2. American Diabetes Association. National Diabetes Fact Sheet. Available at: www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp. Accessed February 23, 2004.


3. Wolfangel P. Addressing the high costs of the diabetes epidemic in the U.S. population. Managed Care. 2004;13(5):4-14.


4. US Physician Database. Available at: www.dr-411.com/physician_specialty_list.asp. Accessed February 23, 2004.


5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.


6. Turner RC, Cull CA, Stratton LM, et al, for the UK Prospective Diabetes Study (UKPDS) Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.


7. Turner RC, Holman RR, Cull CA, et al, for the UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.


8. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA. 1999;261:2005-2012.


9. White JR, Davis SN, Cooppan R, et al. Clarifying the role of insulin in type 2 diabetes management. Clin Diabetes. 2003;21:14-21.

Return to CME Introduction